ebook img

Roche Analyst Event PDF

95 Pages·2015·14.15 MB·English
by  
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Roche Analyst Event

51st ASCO Annual Meeting, Chicago Roche Analyst Event Sunday, 31 May 2015 Agenda Welcome Karl Mahler, Head of Investor Relations Oncology strategy and outlook Daniel O’Day, Chief Operating Officer, Roche Pharmaceuticals Working along the cancer immunity-cycle: Strategies and new agents Ira Mellman, gRED: Ph.D., Vice President, Cancer Immunology, Genentech William Pao, pRED: M.D., Ph.D., Global Head Oncology Discovery and Translational Area, Roche ASCO 2015 Roche highlights: Setting new standards, developing combinations Sandra Horning, M.D., Chief Medical Officer and Head Global Product Development Growing importance of molecular information in cancer immunotherapy Garret Hampton, Ph.D., Vice President, Oncology Biomarker Development and Companion Diagnostics Summary and Q&A Karl Mahler, Head of Investor Relations 2 Oncology strategy and outlook Daniel O’Day Chief Operating Officer, Roche Pharmaceuticals 3 Roche oncology: Continued sales growth A portfolio of differentiated medicines CHF m 24,000 22,000 20,000 18,000 16,000 14,000 12,000 10,000 8,000 10 medicines 16 tumor types 6,000 42 indications 4,000 2,000 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 4 Sales at 2014 average exchange rates Oncology continues to become more complex Science, clinical practice evolving with understanding of disease biology No oncogenic >1 mutated gene 3% driver detected MEK1 <1% 35% y NRAS 1% t i x MET 1% e l PIK3CA KRAS p m BRAF 1% 25% 2% ALK o HER2 3% C Unknown 8% EGFR EGFR (other) 17% PD-L1 positive 4% (illustrative) EGFR KRAS 2004 2014 Today Classification of lung adenocarcinomas 5 Pao & Girard. Lancet Oncol 2011; Johnson, et al. ASCO 2013 Roche’s oncology strategy has remained constant Today’s presentations highlight the results of our strategy across key programs Personalized Strong portfolio & Follow the science healthcare development •  Bringing our best minds •  Differentiation via •  Comprehensive pipeline together biomarkers and active partnering •  Science driven programs •  Experts integrated in R&D •  Smart trial design Higher certainty of patient benefit: Better for patients and for reimbursement 6 Strategy in action - Immunotherapy Perspectives in key franchises Summary 7 Strategy into action: Learning loop Comprehensive and scientifically driven strategies – crafted by our best minds Research Development We bring our best (gRED, pRED, Chugai & (early and late) scientists & clinicians external) together for: •  Ideation Immunotherapy & •  Decision making Combinations •  Quick & efficient pursuit of promising ideas Partnering Clinical Insights ...and we dedicate budget for (Genentech and Roche) & Biomarkers rapid proof of concept (internal and external) studies (Ph1) 8 Atezolizumab (aPD-L1, MPDL3280A) strategy Biomarker selection and combinations Our vision: Bringing the potential for transformative benefit to a broad patient population either in mono therapy or combinations Diagnostic selection to identify Improve survival using well-tolerated patients most likely to benefit from combinations with existing and atezolizumab as a monotherapy emerging therapies PD-L1+ PD-L1+ (tumor – infiltrating (tumor cells) immune cells) 9 Atezolizumab in 2/3L NSCLC (POPLAR) Clinical outcomes correlate with PD-L1 expression Overall Survival Progression Free Survival 0.77 0.98 ITT n=287 0.46 0.57 TC3 or IC3 16%* 0.56 0.70 TC2/3 or IC2/3 37%* 0.63 0.87 TC1/2/3 or IC1/2/3 67%* 1.12 1.17 TC0 and IC0 32%* 1.93 1.87 0 0.5 1 1.5 0 0.5 1 1.5 HRa HRa In favor of atezolizumab In favor of docetaxel In favor of atezolizumab In favor of docetaxel 10 a = Unstratified HR; * = eligible patient population Spira A. et al, ASCO 2015

Description:
ASCO 2015 Roche highlights: Setting new standards, developing combinations Strategy into action: Learning loop . revolution for cancer patients.
See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.